A Hospital Value Analysis Committee Rewards a Five-Sentence Case Over a 17-Page Deck

A hospital value analysis committee is the group that decides whether a new device gets approved for purchase, and it evaluates clinical, financial, and strategic fit together. Most reps walk in prepared to talk about the device.

The committee is prepared to talk about the budget, the risk, and who else in the building needs to sign off first.

Key Takeaways

• Mark Copeland says the surgeon champion is not the one paying the bill, so reps have to make a separate case to whoever controls the budget.
• A hospital value analysis committee responds to a five-to-six-sentence executive business summary; a lengthy clinical deck goes unread.
• Copeland maps every stakeholder's position before requesting a meeting and reports roughly an 82% approval rate after 15 years of using the method.
• Justin Poulin says hospital supply chain now has a seat at the table with the CFO, and it is the number two hospital expense behind staffing.
• Selling only on clinical merit misses two of the three dimensions a value analysis committee weighs: financial and strategic fit.

Watch the full episode on YouTube

A Hospital Value Analysis Committee Rejects Clinical-Only Pitches

A hospital value analysis committee approves a device when the financial and strategic case holds up under its own scrutiny, alongside the clinical one. The vote turns on the budget and strategic fit as much as on what clinicians think.

I interviewed Mark Copeland on an episode about selling to the hospital value analysis committee. He named the mistake reps make from day one:

"Stop thinking just clinical. Stop just calling on doctors and nurses. Stop it. You have to do that, but stop thinking just clinical. You have to think clinical, financial, strategic."

Reps spend years building clinical fluency with surgeons and almost none building financial fluency with the people who approve the purchase. Copeland's framework treats that imbalance as the root cause.

The Surgeon You've Already Won Still Isn't Enough

A clinical champion who loves the device still isn't the person who signs off on buying it. A hospital value analysis committee answers to whoever controls the budget, and that's rarely the surgeon.

Copeland described the exact moment reps misread this:

"Your surgeon champion doesn't care if anybody else comes. He or she just wants the robot for their cases, but he or she is not the ones paying the bill. You got to play upstairs."

A rep with a strong surgeon champion still has to go find whoever owns the budget decision and make a separate case to them, in their own terms, because the sequence matters more than the relationship.

How Mapping Every Stakeholder's Position Builds a Reported 82% Approval Rate

Winning a hospital value analysis committee vote starts well before the meeting where the vote happens. Copeland's process maps every stakeholder's stance before he ever requests that meeting.

He described the method on the same episode:

"I put down the left-hand side, here's all the important people, and across the top I say, are they against us, do they not care, do they love it. And I try to move everybody one to the right."

Copeland says he has run this process for 15 years and reports roughly an 82% approval rate with it, a figure from his own track record rather than a published industry benchmark.

The sequencing matters more than the number, because nobody gets asked for a yes until the rep already knows what everybody in the room thinks, and has spent the time moving the skeptics toward neutral first.

Hospital Supply Chain Now Sits at the Table With the CFO

Hospital supply chain has moved from a back-office function to a seat at the budget table, and a value analysis committee reflects that shift directly.

I interviewed Justin Poulin on an episode about influencing hospital supply chain in medical sales. He explained why that seat exists now:

"They now have a seat at the table with a CFO, and they're also in a position now with healthcare cost savings and uniquely new revenue generation. Supply chain has not been recognized for any revenue generating opportunities in the past."

Supply chain earned that influence with numbers. Poulin pointed out elsewhere in the same conversation that supply chain is the second-largest hospital expense behind staffing, which is exactly the kind of fact a rep needs before walking into that room.

What This Means for Medtech Founders

In my experience working with medtech founders, the reps and companies that win at a hospital value analysis committee treat it as a second sale, as serious as the clinical one that came before it.

That second sale has its own audience, its own language, and its own homework. Map the stakeholders before you ask for the meeting. Build the five-sentence case before anyone asks for the deck. Know who holds the budget before you assume the surgeon does.

This connects to the broader pattern covered in how market engineering changes what medical device sales requires: clinical proof alone was never the whole sale.

Frequently Asked Questions

What is a hospital value analysis committee?

A hospital value analysis committee is the group responsible for approving new medical device and supply purchases. It evaluates clinical evidence, financial return, and strategic fit together, rather than approving a device on clinical merit alone.

Who sits on a hospital value analysis committee?

Membership typically includes clinical staff, supply chain and procurement leaders, finance representatives, and sometimes the CFO directly. The exact mix varies by hospital, which is why mapping each stakeholder's position before a request matters more than knowing a generic org chart.

How do you prepare for a hospital value analysis committee presentation?

Build a five-to-six-sentence executive business summary covering the problem, the investment, and the return, and map where every stakeholder stands before requesting the meeting.

A committee that already has a sense of where the room stands moves faster than one hearing every argument for the first time in the room.

Why does a hospital value analysis committee reject strong clinical data?

Strong clinical data alone proves the device works. It doesn't prove the hospital can afford it, that supply chain can manage it, or that it fits the hospital's strategic goals, and a value analysis committee weighs all three before it weighs the clinical case alone.

Where to Go From Here

If you're doing this yourself. Read the pillars of market engineering to see how the sales case to a value analysis committee fits into the broader commercial sequence.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. For founders whose reps are stalling at committee, the audit flags where the financial and strategic case is missing.

Listen to the Full Conversations

• Secrets to Selling to the Hospital Value Analysis Committee with Mark Copeland
• How to Influence Hospital Supply Chain in Medical Sales with Justin Poulin

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry. He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth.

Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.